HIV Aids
Aids Update
Successful AIDS Trial
Dr. Fernandez and GMT performed a PHASE 1 Government Approved Controlled Clinical Trial in 36 patients with HIV/AIDS in the Dominican Republic in 2004-2005. This study demonstrated viral load counts reduction by 75-99% within 90 days, with a stabilization in CD4/CD8 counts and the complete disappearance of opportunistic infections. This study further demonstrated a tenfold improvement in the quality of life of those treated.
From 2006 to 2009 Dr. Fernandez and GMT performed a 29 month Pilot Study on 7 patients with HIV/AIDS in Colombia from 2006-2008 and a 2007-2008 Pilot Study in Laminitis; the second leading cause of death in cattle and horses. The successful accomplishments of these two Pilot studies, answered several questions that both the Colombian Government and Universities had prior to the completion of our 29 month Pilot Study.
First, could we repeat the results obtained in the Dominican Republic and could we guarantee a reduction in costs to keep one person alive with HIV/AIDS by 90%. The answer to both these question was a resounding yes. GMT proved that the treatment does indeed reduce viral loads, stabilized CD4/CD8 cells and eliminates 100% of opportunistic infections (main reason why people with HIV die), whereby increasing the quality of life tenfold in addition to decreasing the costs by 93% across the board.
Due to these results, the Government of Colombia as well as, the Academic Sponsorship from two Universities, Laboratories, and a Government Public Hospital have agreed to perform the following clinical and laboratory studies with GMT:
-
Phase II Controlled Clinical Trials in 200 Patients with HIV/AIDS,
-
Phase I Controlled Clinical Trials in 100 Patients with Leishmaniasis,
-
Phase I Controlled Clinical Trials in 100 Horses/Cattle with Laminitis,
-
Phase I Laboratory Trials for Blood Sterilization Process and
-
Phase I Laboratory Trials for Organ Transplant Sterilization Process.
Over the next several years, GMT plans on completing multiple clinical trials in targeted demographic regions around the world as an integral part of our biomedical research and development program which will ensure the use of their biomedical technologies, applications and treatments as both a viable and cost efficient medical treatment for many diseases that affect both the human and animal species.
This photo shows a patient that was treated in our Pilot Study in Colombia. When she first arrived at our study, she weighed approximately 100 lbs. She suffered from Chronic HIV/AIDS and multiple opportunistic infections (pneumonia, chronic dermatitis, wasting syndrome, no appetite). During the course of our Pilot Study, she did not take any antiviral cocktails and all of her opportunistic infections dissipated.
HIV Aids
The GlobalMed Journey began with HIV Aids
GMT had to start somewhere and decided to commence in 2002 with HIV/AIDS. Despite the current COVID19 Pandemic, Aids is an issue and a disease that has touched many of our lives, especially that of Dr. Fernandez who has witnessed the needless loss of friends, patients, associates, and family members to HIV.
HIV is accompanied by many co-infections known as “Opportunistic Infections” or “OIs” and these infections cause the ultimate human death, and not the HIV virus itself. The OI’s proliferate because HIV has depleted the person’s immune (defense) system to a point where it can no longer defend itself.
Most life-threatening OIs occur when a person’s CD4 (immune defense cells) count is below 200 cells/mm3. The CDC developed a list of more than 20 OIs that are considered AIDS-defining conditions—if a person has HIV and one or more of these OIs, they will be diagnosed with AIDS, no matter what your CD4 count is: Candidiasis of the bronchi, trachea, esophagus, or lungs, Invasive cervical cancer, Coccidioidomycosis, Cryptococcosis, Cryptosporidiosis, (chronic intestinal parasitic infection -greater than 1 month’s duration), Cytomegalovirus disease (particularly CMV retinitis), Encephalopathy, HIV-related Herpes simplex: chronic ulcer(s) (greater than 1 month’s duration); or bronchitis, pneumonitis, or esophagitis, Histoplasmosis, Isosporiasis, chronic intestinal (greater than 1 month’s duration), Kaposi’s sarcomav, Lymphoma, multiple forms, Mycobacterium avium complex, Tuberculosis, Pneumocystis carinii pneumonia, Pneumonia, recurrent, Progressive multifocal leukoencephalopathy, Salmonella septicemia, recurrent, Toxoplasmosis of brain and Wasting syndrome due to HIV.
Read More...
Incredible as it may seem, Retro-Viral medications “DO NOT KILL THE HIV VIRUS”. Retrovirals only function by “PROHIBITING THE VIRUS TO MULTIPLY” and if the virus cannot multiply (replicate or copy itself) then it eventually dies. But when a virus like HIV has the capability to “RESIST” (meds don’t work) the retrovirals then become obsolete and must be changed. Hence the expensive “Cocktails” known in HIV medication lingo.
If a patient becomes resistant to one regiment of retrovirals, then the doctor changes up the “Cocktail” of medications and mixes and matches a new regiment. There are currently over 30 medications created for the treatment of HIV and the mixing and matching of these are known as the “cocktails”. When a person with HIV has exhausted all the possible cocktails, (which takes 20 years) they succumb to the disease and the OIs.
GMT choose HIV for its initial trial to determine if and how PCI worked on HIV because if that was the case, it was believed that it would also work on all the different OIs. We were pleased to see that the PCI treatment not only lowered HIV Viral Loads but it also worked and all OIs presented (during our Government Approved Controlled Phase I Clinical Trials in the Dominican Republic in 2004-2005).
GMT tested 36 patients with full-blown HIV Aids and found that all OIs disappeared within one month of treatment. In most cases, the milder onset of OI’s disappeared within the first two weeks. GlobalMed achieved a decrease in Viral Loads by 90% within three months, a stabilization in CD4/CD8 (immune cells) counts, a total disappearance of OIs, and a tenfold increase in quality of life. Nothing like this had been seen in any clinical trial to date.
Doctors treating HIV Aids around the world have had one primary struggle – what to do about the OIs that do not respond to any kind of conventional treatment? With GMT’s PCI treatment, OIs will be nothing more than a nuance that can be readily treated with the PCI treatment. As long as the patients were receiving treatments none of the OIs returned throughout the duration of the trials. This fact brought to mind the ability of PCI to not only eliminate the OIs but to afford the patient protection against any other infection while on treatment. These patients could literally go out and get next to anyone sick with a severe rhinovirus (common cold) and they would not become infected; even with their depleted immune systems.
GMT’s next objective is to complete our Government Approved Controlled Phase II and III Clinical Trials in, 200 and 1,000 patients respectively, with HIV/AIDS. These clinical trials will compare the effectiveness of PCI in contrast to the known Retroviral “Cocktails”, as well as the cost viability of PCI compared to current retroviral medications costs.
GMT looks to a bright future where we prove beyond a shadow of a doubt the effectiveness and viability of PCI as a treatment of choice for all infectious diseases including HIV Aids.
